News | June 17, 2008

Bracco Breaks the Mold with Cardiac PET Perfusion Imaging

June 18, 2008 – Bracco Diagnostics showcased its Cardiac PET Perfusion Imaging with CardioGen-82, a Rubidium Rb 82 generator and emphasized the advantages of cardiac PET Perfusion Imaging over the current SPECT, at the Society of Nuclear Medicine's 55th Annual Meeting.

The Rb-82/Sr-82 generator, which is FDA cleared, has Sr-82 on the column. When Sr-82 decays, it decays to a new daughter product called Rb-82. The physical half-life for Rb-82 is 75 seconds, which allows for an efficient protocol. By the time the imaging is completed for the rest portion (approximately 6 minutes), stress can follow immediately and then the stress images can be acquired (approximately 6 minutes). The study can be completed in approximately 40-45 minutes.

Key features of Rb-82 are that it has properties similar to Thallium-201 (Tl-201). Rb-82 acts as a potassium analog, allowing for a high extraction fraction at high flow rates. Defects are visualized within 2 – 7 minutes after injection. Due to the short T_ (75 seconds), both sets of images can be acquired using the same sized dose. A new 100 mCi generator arrives every 28 days. Fixed pricing allows many patients to be performed in a day without the hassle of ordering unit doses. All studies are performed under pharmacologic stress (e.g., adenosine, dipyridamole, or dobutamine)

Some of the advantages of cardiac PET Perfusion Imaging over the current SPECT, according to the company are: improved efficiency; lower radiation; exposure; less attenuation artifacts; and improved resolution.

For more information: www.bracco.com

Related Content

Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...